YOU ARE HERE >
MONEYCONTROL >
MARKETS >
Pharmaceuticals
> Consolidated Nine Months - Ranbaxy Laboratories
Ranbaxy Laboratories
BSE: 500359|NSE: RANBAXY|ISIN: INE015A01028|SECTOR: Pharmaceuticals
LIVE
BSE
May 29, 14:54
538.50
13.8 (2.63%)VOLUME 324,130
LIVE
NSE
May 29, 14:54
538.80
13.6 (2.59%) VOLUME 1,594,008
Consolidated Nine Months of Ranbaxy Laboratories |
------------------- in Rs. Cr. ------------------- |
 | |||||||||
|
|||||||||
| Sep '11 | Sep '10 | Sep '07 | Sep '06 | ||||||
|
|||||||||
| Sales Turnover | 6,369.11 | 6,852.36 | 6,359.40 | 1,627.10 | |||||
| Other Income | 270.85 | 202.44 | 276.90 | -18.40 | |||||
| Total Income | 6,639.95 | 7,054.80 | 6,636.30 | 1,608.70 | |||||
| Total Expenses | 5,902.20 | 5,120.01 | 5,370.50 | 1,358.80 | |||||
| Operating Profit | 466.91 | 1,732.35 | 988.90 | 268.30 | |||||
| Profit On Sale Of Assets | -- | -- | -- | -- | |||||
| Profit On Sale Of Investments | -- | -- | -- | -- | |||||
| Gain/Loss On Foreign Exchange | -- | -- | -- | -- | |||||
| VRS Adjustment | -- | -- | -- | -- | |||||
| Other Extraordinary Income/Expenses | -- | -- | -- | -- | |||||
| Total Extraordinary Income/Expenses | -248.57 | 485.67 | 22.30 | -- | |||||
| Tax On Extraordinary Items | -- | -- | -- | -- | |||||
| Net Extra Ordinary Income/Expenses | -- | -- | -- | -- | |||||
| Gross Profit | 737.76 | 1,934.79 | 1,265.80 | 249.90 | |||||
| Interest | 46.39 | 46.86 | 132.60 | 23.20 | |||||
| PBDT | 442.79 | 2,373.60 | 1,155.50 | 226.70 | |||||
| Depreciation | 225.89 | 268.74 | 229.20 | 49.60 | |||||
| Depreciation On Revaluation Of Assets | -- | -- | -- | -- | |||||
| PBT | 216.90 | 2,104.86 | 926.30 | 177.10 | |||||
| Tax | 122.26 | 496.92 | 196.40 | 37.80 | |||||
| Prior Years Income/Expenses | -- | -- | -- | -- | |||||
| Net Profit | 94.64 | 1,607.94 | 729.90 | 139.30 | |||||
| Minority Interest | -6.80 | -9.25 | -- | -- | |||||
| Share Of P/L Of Associates | -4.80 | -4.46 | -- | -- | |||||
| Net P/L After Minority Interest & Share Of Associates | 83.04 | 1,594.23 | 729.90 | 139.30 | |||||
| Depreciation for Previous Years Written Back/ Provided | -- | -- | -- | -- | |||||
| Dividend | -- | -- | -- | -- | |||||
| Dividend Tax | -- | -- | -- | -- | |||||
| Dividend (%) | -- | -- | -- | -- | |||||
| Earnings Per Share | 2.25 | 38.22 | 19.56 | 3.74 | |||||
| Book Value | -- | -- | -- | -- | |||||
| Equity | 210.75 | 210.38 | 186.54 | 186.33 | |||||
| Reserves | -- | -- | -- | -- | |||||
| Face Value | 5.00 | 5.00 | 5.00 | 5.00 | |||||
| |||||||||
| Source : Dion Global Solutions Limited | |||||||||
| |||||||||
Results of Ranbaxy Labs
- News
- Results
- Estimates
- Analysis
Results of Pharmaceuticals Sector
- News
- Results
- Estimates
- Analysis
Quick Links for ranbaxylaboratories
Related Searches
ranbaxylaboratories Stock Price, Ranbaxy%20Labs Stock Quote, Ranbaxy%20Labs Results , Ranbaxy%20Labs News ..
More »
Follow moneycontrol.com
Explore Moneycontrol
Mutual Funds
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
News |
Markets |
IPO |
Technicals |
Mutual Fund |
Commodities |
Best Portfolio Manager |
Bse Sensex |
Bombay Stock Exchange |
Share Market Live |
Recession 2011 |
Commodities Price |
Silver Price/Rate in India |
Gold Price/Rate in India |
Crude Oil |
USD to INR |
National Stock Exchange |
Bank Fixed Deposits |
Company Fixed Deposits |
Small Savings Schemes |
Property rates in India |
Rss Feeds | Budget:2008, 2009, 2010, 2011, 2012 |
Intuit Money Manager |
RBI Credit Policy | BSE A Group Companies | BSE B Group Stocks | Union Budget
| Financial Glossary
|
Message Board |
Moneybhai |
Connect.in.com |
Business Yellow Pages |
India's Premiere Technology Guide |
History India | Davos
| Air India | Cyrus Mistry | Bajaj | UBS AG | Morgan Stanley | Ranbaxy Laboratories | BSE Sensex | Sheila Dikshit | Gasoline | Tata Motors
Site Map | About Us | Contact Us | Advertise | Bookmark | Disclaimer | Privacy Statement | Terms of Use | Careers
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.